10-Q: BioScience Health Innovations Reports Strong 9-Month Growth

BioScience Health Innovations Inc. reported significant revenue and net income growth for the nine months ended September 30, 2025, driven by strategic initiatives and product development, despite a net loss in the most recent quarter.

Summary

• Revenue for the nine months ended September 30, 2025, increased significantly to $4,115,960, up from $1,234,744 for the same period in 2024.
• Net income for the nine months ended September 30, 2025, was $875,720, a substantial increase from $77,043 in the prior year period.
• The company reported a net loss of $8,782 for the three months ended September 30, 2025, compared to a net income of $56,202 for the same quarter in 2024.
• Cash and cash equivalents increased to $1,139,423 as of September 30, 2025, from $662,517 at December 31, 2024.
• Total assets grew to $2,067,100 as of September 30, 2025, from $873,788 at December 31, 2024.
• The company changed its corporate name to BioScience Health Innovations Inc. on February 21, 2025, and completed a 1-for-4 reverse common stock split on September 10, 2025.
• Six patent applications are pending for core delivery technologies, including the MODS Max (Mineral Oxide Delivery System) platform, which is expected to create 5-10 years of market exclusivity.
• Management identified material weaknesses in internal control over financial reporting, including a lack of sufficient accounting resources, inadequate segregation of duties, absence of an independent board/audit committee, and lack of written control documentation.

Sentiment

Score: 7

Explanation: The company shows strong growth in revenue and net income for the nine-month period, significant cash increase, and promising strategic initiatives with multiple patent applications. However, the net loss in the most recent quarter, coupled with identified material weaknesses in internal controls and ongoing 'going concern' doubt, introduces notable risks and tempers overall sentiment.

Positives

• Achieved substantial revenue growth of 233% for the nine months ended September 30, 2025, reaching $4,115,960.
• Reported significant net income of $875,720 for the nine months ended September 30, 2025, compared to $77,043 in the prior year.
• Cash and cash equivalents increased by 72% to $1,139,423 as of September 30, 2025.
• Accumulated earnings shifted from a deficit of $(341,083) to positive earnings of $534,637.
• Generated positive cash flow from operating activities of $272,874 for the nine months ended September 30, 2025.
• Secured six pending patent applications for innovative delivery technologies, including MODS Max, offering potential market exclusivity for 5-10 years.
• Clinical validation for the patent-pending enclomiphene delivery system shows average testosterone improvements of 56.3%.
• MODS Max technology demonstrates enhanced absorption (10x increased permeability), broad-spectrum antimicrobial activity, universal compatibility, and superior 18-month shelf stability.
• Strategic partnerships with 10X Health, DaVinci Medical, and The Wellness Company are leveraging established audiences.
• Initiated steps for product registration in Dubai, opening opportunities for entry into Middle Eastern markets.
• Prepaid for one year of comprehensive Director and Officers (D&O) insurance, including cybersecurity coverage, enhancing executive protection and corporate governance.

Negatives

• Reported a net loss of $8,782 for the three months ended September 30, 2025, a decline from a net income of $56,202 in the comparable prior year quarter.
• Management concluded that disclosure controls and procedures were ineffective as of September 30, 2025.
• Identified material weaknesses in internal control over financial reporting, including a lack of sufficient internal accounting resources, inadequate segregation of duties, absence of an independent board of directors or audit committee, and lack of written control policies.
• The company's ability to continue as a going concern is dependent on its ability to generate sufficient revenue and raise additional funds, despite recent profitability.
• Continued reliance on advances from related parties, with $2,422,096 received and $2,172,000 repaid during the nine months ended September 30, 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to historical losses and reliance on external financing, despite recent profitability.
• Ineffective disclosure controls and procedures as of September 30, 2025.
• Material weaknesses in internal control over financial reporting, including insufficient internal accounting resources, lack of segregation of duties, absence of an independent board or audit committee, and lack of written control documentation.
• Dependence on related party advances for cash requirements until adequate financing is attained through equity sales or traditional debt.
• Risks inherent in marketing products in a competitive market, including potential cost overruns due to price and cost increases in services and products.
• The company has not implemented specific policies for monitoring and managing cybersecurity threats, although it recognizes the importance and is taking proactive steps.

Future Outlook

Management is optimistic about carving out profitable positions in the mental health and general wellness markets, particularly through patent-pending Methylene Blue products and other specialty offerings. The company plans to focus on gaining traction for these products, capitalizing on the growing interest in mitochondrial health. Strategic initiatives include pursuing partnerships, expanding into international markets like Dubai, and enhancing digital infrastructure with an upgraded website and integrated accounting systems. The company aims for sustainable long-term expansion in both US and global markets, with a commitment to innovation-led growth, capital structure optimization, and regulatory progress, including preparation for a Nasdaq uplisting.

Management Comments

• "As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings."
• "We believe we are very well positioned and with adequate capital infusion we will be able to capitalize on multiple market opportunities."
• "The strengthening of our intellectual property portfolio through multiple patent applications, trademark protections, and domain acquisition, combined with our enhanced digital infrastructure, integrated accounting systems, and comprehensive executive liability insurance coverage, creates significant competitive moats and positions us for enhanced brand protection, premium pricing capabilities, and accelerated market expansion across our target therapeutic areas."
• "Our proactive approach to corporate governance and executive protection through comprehensive D&O insurance demonstrates our commitment to best practices as we prepare for Nasdaq uplisting and operate under the heightened standards expected of public companies."
• "With MODS Max addressing multiple billion-dollar healthcare markets and demonstrating exceptional clinical validation across diverse patient populations, we are well-positioned to capture significant market share while delivering transformative health outcomes."

Industry Context

BioScience Health Innovations operates in the rapidly expanding immune health supplement and broader health and wellness markets, with a particular focus on mental health, cognitive support, and mitochondrial health. The company's emphasis on patent-pending technologies like MODS Max and Methylene Blue stabilization positions it within the innovative segment of therapeutic delivery and nutraceuticals. The targeting of large addressable markets such as Oral GLP-1 Agonists ($156.7B by 2030-2033), Testosterone Replacement Therapy ($2.79B), and the Longevity Market ($63.0B by 2035) aligns with major healthcare trends. The company's strategy to partner with compounding pharmacies and leverage direct-to-consumer channels reflects a modern approach to market penetration, aiming to disrupt traditional pharmaceutical and supplement distribution.

Comparison to Industry Standards

• The company's patent-pending enclomiphene delivery system demonstrates breakthrough clinical validation with average testosterone improvements of 56.3%, which is a strong indicator of efficacy compared to standard treatments.
• The patent-pending methylene blue stabilization technology aims to address a significant industry challenge, as standard formulations reportedly lose 50% potency within 3 days, suggesting a superior product if stability studies confirm potency retention.
• The MODS Max technology's claim of over 10x increased permeability for nutrient absorption could set a new benchmark for bioavailability in the supplement and drug delivery industry, potentially outperforming many existing oral delivery methods.
• The company's projected 65%+ margins via website subscriptions and product packs are indicative of a high-value product strategy, potentially exceeding typical margins for commodity health supplements.
• The company's plan to pursue FDA 505(b)(2) pathway classification for its sublingual delivery technology suggests an ambition to achieve regulatory advantages and competitive differentiation, similar to how other innovative drug delivery companies seek accelerated approval for new dosage forms.

Corporate Governance

Related Party Transactions

• Received advances of $2,422,096 from Ageless Holdings, LLC (an entity owned and controlled by the company's management and board of directors) during the nine months ended September 30, 2025.
• Repaid $2,172,000 of advances to related parties during the nine months ended September 30, 2025.
• Subsequent to September 30, 2025, received additional advances of $58,604 from related parties and made repayments of $150,000.

Stakeholder Impact

• Shareholders: Experience potential dilution from future capital raises, impact from the 1-for-4 reverse stock split, and benefit from significant year-to-date revenue and net income growth, but face risks from the Q3 net loss and internal control weaknesses.
• Employees: Potential for increased hiring, particularly in accounting, once sufficient capital is raised.
• Customers: Benefit from new and improved product offerings, enhanced delivery systems, and an upgraded e-commerce experience.
• Creditors: The company's reliance on related party advances for funding may be a consideration, though recent profitability and cash flow improvements are positive.
• Management/Board: Benefit from comprehensive D&O insurance, but are responsible for addressing identified material weaknesses in internal controls and navigating the 'going concern' doubt.

Next Steps

• Raise additional funds through a private or public offering to support long-term operations.
• Establish written policies and procedures for internal control over financial reporting.
• Hire additional accounting personnel to address internal control weaknesses, contingent on raising sufficient capital.
• Continue stability studies for patent-pending methylene blue stabilization technology and sublingual delivery technology.
• Actively explore partnerships and strategic alliances to maximize value for stakeholders, particularly for MODS Max technology.
• Complete product registration in Dubai to facilitate entry into Middle Eastern health and wellness markets.
• Launch the upgraded best365labs.com retail and wholesale website with integrated NetSuite platform (targeted August 2025).
• Evaluate additional global registration and commercialization pathways for MODS Max and proprietary product lines.
• Prepare for Nasdaq uplisting, adhering to heightened standards expected of public companies.

Key Dates

Recommendation

While BioScience Health Innovations Inc. demonstrates impressive year-to-date revenue and net income growth, significant cash accumulation, and a robust pipeline of patent-pending technologies targeting high-growth markets, several critical factors warrant a 'hold' recommendation. The net loss in the most recent quarter, coupled with the explicit 'going concern' doubt and identified material weaknesses in internal controls, presents substantial operational and financial risks. The company's continued reliance on related party financing, despite positive operating cash flow, indicates ongoing funding challenges. A seasoned investor would likely await consistent quarterly profitability, clear remediation of internal control deficiencies, and a more diversified funding strategy before considering a 'buy' recommendation. The strategic initiatives are promising, but execution and risk mitigation are paramount.

Keywords

BioScience Health Innovations, MODS Max, Methylene Blue, Health and Wellness, SEC Filing, 10-Q, Biotechnology, Pharmaceuticals, Nutraceuticals, Patent Pending, Mitochondrial Health, Testosterone Replacement Therapy, GLP-1 Agonists, Compounding Pharmacy, Corporate Governance, Internal Controls